当前位置: X-MOL 学术Brazilian Journal of Psychiatry › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
N-acetylcysteine as an adjunctive treatment for smoking cessation: a randomized clinical trial
Brazilian Journal of Psychiatry ( IF 5.5 ) Pub Date : 2020-10-01 , DOI: 10.1590/1516-4446-2019-0753
Regina C.B.R. Machado 1 , Heber O. Vargas 1 , Marcela M. Baracat 2 , Mariana R. Urbano 3 , Waldiceu A. Verri Jr 3 , Mauro Porcu 1 , Sandra O.V. Nunes 4
Affiliation  

Objective: This randomized controlled trial examined the efficacy and safety of N-acetylcysteine as an adjunctive treatment for smoking cessation. Methods: Heavy smokers were recruited from smoking cessation treatment for this 12- week randomized controlled trial. Eligible tobacco use disorder outpatients (n=34) were randomized to N-acetylcysteine or placebo plus first-line treatment. Abstinence was verified by exhaled carbon monoxide (COexh). The assessment scales included the Fagerström Test for Nicotine Dependence, the Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, the Minnesota Nicotine Withdrawal Scale, and the Medication Adherence Rating Scale. We also assessed anthropometrics, blood pressure, lipid profile, and soluble tumor necrosis factor receptor (sTNF-R) levels 1 and 2. Results: First-line treatment for smoking cessation plus adjunctive N-acetylcysteine or placebo significantly reduced COexh (p < 0.01). In the N-acetylcysteine group, no significant changes were found in nicotine withdrawal symptoms, depressive and anxiety symptoms, anthropometric measures, blood pressure, or glucose compared to placebo. However, there was a significant reduction in sTNF-R2 levels between baseline and week 12 in the N-acetylcysteine group. Conclusions: These findings highlight the need to associate N-acetylcysteine with first-line treatment for smoking cessation, since combined treatment may affect inflammation and metabolism components. Clinical trial registration: NCT02420418

中文翻译:

N-乙酰半胱氨酸作为戒烟的辅助治疗:一项随机临床试验

目的:这项随机对照试验检查了 N-乙酰半胱氨酸作为戒烟辅助治疗的有效性和安全性。方法:在这项为期 12 周的随机对照试验中,从戒烟治疗中招募了重度吸烟者。符合条件的烟草使用障碍门诊患者 (n=34) 随机接受 N-乙酰半胱氨酸或安慰剂加一线治疗。通过呼出的一氧化碳 (COexh) 验证戒烟。评估量表包括尼古丁依赖的 Fagerström 测试、汉密尔顿抑郁量表、汉密尔顿焦虑量表、明尼苏达尼古丁戒断量表和药物依从性量表。我们还评估了人体测量学、血压、血脂和可溶性肿瘤坏死因子受体 (sTNF-R) 水平 1 和 2。 结果:戒烟的一线治疗加辅助 N-乙酰半胱氨酸或安慰剂显着降低了 COexh(p < 0.01)。在 N-乙酰半胱氨酸组中,与安慰剂相比,在尼古丁戒断症状、抑郁和焦虑症状、人体测量、血压或血糖方面没有发现显着变化。然而,在 N-乙酰半胱氨酸组中,sTNF-R2 水平在基线和第 12 周之间显着降低。结论:这些发现强调需要将 N-乙酰半胱氨酸与戒烟的一线治疗联系起来,因为联合治疗可能会影响炎症和代谢成分。临床试验注册:NCT02420418 与安慰剂相比,在尼古丁戒断症状、抑郁和焦虑症状、人体测量、血压或血糖方面没有发现显着变化。然而,在 N-乙酰半胱氨酸组中,sTNF-R2 水平在基线和第 12 周之间显着降低。结论:这些发现强调需要将 N-乙酰半胱氨酸与戒烟的一线治疗联系起来,因为联合治疗可能会影响炎症和代谢成分。临床试验注册:NCT02420418 与安慰剂相比,在尼古丁戒断症状、抑郁和焦虑症状、人体测量、血压或血糖方面没有发现显着变化。然而,在 N-乙酰半胱氨酸组中,sTNF-R2 水平在基线和第 12 周之间显着降低。结论:这些发现强调需要将 N-乙酰半胱氨酸与戒烟的一线治疗联系起来,因为联合治疗可能会影响炎症和代谢成分。临床试验注册:NCT02420418 这些发现强调需要将 N-乙酰半胱氨酸与戒烟的一线治疗联系起来,因为联合治疗可能会影响炎症和代谢成分。临床试验注册:NCT02420418 这些发现强调需要将 N-乙酰半胱氨酸与戒烟的一线治疗联系起来,因为联合治疗可能会影响炎症和代谢成分。临床试验注册:NCT02420418
更新日期:2020-10-01
down
wechat
bug